Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Computing
Conference & Expo
November 2-4, 2009 NYC
Register Today and SAVE !..

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
In many cases, the end of the year gives you time to step back and take stock of the last 12 months. This is when many of us take a hard look at what worked and what did not, complete performance reviews, and formulate plans for the coming year. For me, it is all of those things plus a time when I u...
SYS-CON.TV
Lakewood-Amedex Inc. Appoints Marie E. Knight To Its Board Of Directors

SARASOTA, Fla., Dec. 4, 2012 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has elected Marie E. Knight to its board of directors.  Dr. Knight brings to the company her experience in both biotechnology equity research, including significant connections in the equity financing arena, and her years of high-level consulting on market intelligence in the pharmaceutical industry.  Dr. Knight will initially focus on helping the company to raise expansion capital and provide regulatory guidance as it prepares to move its Nu-2 topical anti-bacterial product to IND filing and into Phase I clinical trials in 2013. 

Dr. Knight has over 20 years in the healthcare industry, including 14 years in pharmaceutical and biotechnology equity research and as a consultant for numerous multinational pharmaceutical companies.  As a Senior Biotech Analyst at Avalon Research Group, a NASD research sell-side firm, she provided drug-pipeline analysis of publicly traded biotechnology companies and evaluation of venture capital opportunities.   She also has first-hand industry experience working at a small biotech company as a traveling developmental scientist.  In this capacity, she worked on-site for many pharmaceutical and biotech companies and collaborated with industry scientists at all stages of drug development, including basic research, pharmacokinetics, toxicology, QC, clinical testing, and manufacturing.  

She brings an international perspective as a consultant working for the last ten years with pharmaceutical teams across numerous therapeutic areas to provide actionable strategic direction.  In this role she has provided research and analysis for oncology, rheumatology, ophthalmology, infectious diseases and immunology projects, both for pre-approval and post-marketed products. 

Lakewood-Amedex's President and CEO, Steve Parkinson, commented "It is a pleasure to welcome a world-class executive of Marie Knight's standing to the board of directors.  Her hands-on intimate familiarity with the drug-development process will be invaluable in working with our team to successfully commercialize our products.  This experience brings to Lakewood-Amedex additional capabilities to navigate the regulatory environment and maximize assets to best align with future potential licensing and partnership opportunities."

Dr. Knight commented "Having researched many biotechnology companies in my time, I was greatly impressed with the breadth of the Lakewood-Amedex product portfolio and the quality of the company's science.  This sets them apart from most companies at this stage of development.  Also the management team has the right level of passion and chemistry that I can work with to help them make a great success of this very promising company.  I have already initiated communications with the FDA.  We expect to move the first product forward into the clinic rapidly and really put this company on the map."

About Lakewood-Amedex, Inc.

Lakewood-Amedex is a privately held biopharmaceutical company developing a broad portfolio of anti-infective products, including first-in-class anti-bacterial compounds, orally available nanoRNA therapeutics for acute and chronic diseases such as arthritis, inflammation, cancer, influenza, and hepatitis, and a fully human monoclonal antibody for HUS.  The Company's products and technology are covered by an extensive patent portfolio consisting of 36 granted and/or issued patents and 29 pending patent applications filed on a worldwide basis covering all major pharmaceutical markets.  The Company's lead therapeutic candidate is a novel synthetic broad spectrum anti-bacterial proven to be effective in killing a wide range of gram-positive, gram-negative, and antibiotic-resistant bacteria and is expected to enter the clinic in 2013.

This press release contains forward-looking statements that can be identified by terminology such as "expects", "potential", "suggests", "may", "will" or similar expressions.  Such forward-looking statements regarding our business, which are not historical facts, are "forward-looking statements" that involve risk and uncertainties, which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements.  Actual results may differ materially from statements made as a result of various factors, including, but not limited to sufficiency of cash to fund the Company's planned operations, risk associated with inherent uncertainty of product research and development, risk of protecting proprietary rights and competition.  Forward-looking statements speak only as to the date they are made.  The Company does not undertake to update forward-looking statements to reflect the circumstances or events that occur after the date the forward-looking statements are made.

Contacts:




Steve Parkinson

Marie E. Knight

President and CEO

Director

Lakewood-Amedex Inc.

Lakewood-Amedex, Inc.

(941) 255 2515

(321) 223 3152

sparkinson@lakewoodamedex.com 

mknight@lakewoodamedex.com

SOURCE Lakewood-Amedex Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

SOA World Latest Stories
Verizon Enterprise Solutions is simplifying the cloud-purchasing experience for its clients, with the launch of Verizon Cloud Marketplace, a key foundational component of the company's robust ecosystem of enterprise-class technologies. The online storefront will initially feature pre-b...
"People are a lot more knowledgeable about APIs now. There are two types of people who work with APIs - IT people who want to use APIs for something internal and the product managers who want to do something outside APIs for people to connect to them," explained Roberto Medrano, Execut...
“We are a managed services company. We have taken the key aspects of the cloud and the purposed data center and merged the two together and launched the Purposed Cloud about 18–24 months ago," explained Chetan Patwardhan, CEO of Stratogent, in this SYS-CON.tv interview at 15th Cloud Ex...
The Internet of Things is a misnomer. That implies that everything is on the Internet, and that simply should not be - especially for things that are blurring the line between medical devices that stimulate like a pacemaker and quantified self-sensors like a pedometer or pulse tracker....
"Ulunsoft is a start-up that focuses on how enterprises build cloud-based IT infrastructure for business," explained Haibo Zhu, President of Ulunsoft Corp, in this SYS-CON.tv interview at Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
As enterprises engage with Big Data technologies to develop applications needed to meet operational demands, new computation fabrics are continually being introduced. To leverage these new innovations, organizations are sacrificing market opportunities to gain expertise in learning new...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021


SYS-CON Featured Whitepapers
ADS BY GOOGLE